Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.10
PTX's Cash-to-Debt is ranked lower than
91% of the 719 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.89 vs. PTX: 0.10 )
Ranked among companies with meaningful Cash-to-Debt only.
PTX' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.02  Med: 0.72 Max: No Debt
Current: 0.1
Equity-to-Asset -0.08
PTX's Equity-to-Asset is ranked lower than
97% of the 660 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.62 vs. PTX: -0.08 )
Ranked among companies with meaningful Equity-to-Asset only.
PTX' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.08  Med: 0.43 Max: 0.99
Current: -0.08
-0.08
0.99
Piotroski F-Score: 1
Altman Z-Score: -1.47
Beneish M-Score: -4.69
WACC vs ROIC
11.80%
-44.88%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating Margin % -72.81
PTX's Operating Margin % is ranked lower than
86% of the 672 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.86 vs. PTX: -72.81 )
Ranked among companies with meaningful Operating Margin % only.
PTX' s Operating Margin % Range Over the Past 10 Years
Min: -72.81  Med: -1.86 Max: 33
Current: -72.81
-72.81
33
Net Margin % -105.17
PTX's Net Margin % is ranked lower than
88% of the 673 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 5.73 vs. PTX: -105.17 )
Ranked among companies with meaningful Net Margin % only.
PTX' s Net Margin % Range Over the Past 10 Years
Min: -105.17  Med: -2.3 Max: 33.08
Current: -105.17
-105.17
33.08
ROE % -717.76
PTX's ROE % is ranked lower than
99% of the 690 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.66 vs. PTX: -717.76 )
Ranked among companies with meaningful ROE % only.
PTX' s ROE % Range Over the Past 10 Years
Min: -717.76  Med: -1.76 Max: 137.29
Current: -717.76
-717.76
137.29
ROA % -35.36
PTX's ROA % is ranked lower than
85% of the 721 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.48 vs. PTX: -35.36 )
Ranked among companies with meaningful ROA % only.
PTX' s ROA % Range Over the Past 10 Years
Min: -35.36  Med: -0.75 Max: 68.03
Current: -35.36
-35.36
68.03
ROC (Joel Greenblatt) % -5310.06
PTX's ROC (Joel Greenblatt) % is ranked lower than
95% of the 710 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 13.44 vs. PTX: -5310.06 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
PTX' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -5335.54  Med: -0.8 Max: 1558.21
Current: -5310.06
-5335.54
1558.21
3-Year Revenue Growth Rate 14.80
PTX's 3-Year Revenue Growth Rate is ranked higher than
74% of the 600 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.00 vs. PTX: 14.80 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
PTX' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: 0  Med: 9.1 Max: 105.4
Current: 14.8
0
105.4
3-Year EPS without NRI Growth Rate 281.70
PTX's 3-Year EPS without NRI Growth Rate is ranked higher than
100% of the 541 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.50 vs. PTX: 281.70 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
PTX' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: 0  Med: -63.2 Max: 281.7
Current: 281.7
0
281.7
GuruFocus has detected 7 Warning Signs with Pernix Therapeutics Holdings Inc $PTX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» PTX's 10-Y Financials

Financials (Next Earnings Date: 2017-06-10 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

PTX Guru Trades in Q1 2016

Steven Cohen 2,500,000 sh (+138.09%)
Paul Tudor Jones Sold Out
Jim Simons 131,937 sh (-84.44%)
» More
Q2 2016

PTX Guru Trades in Q2 2016

Paul Tudor Jones 215,800 sh (New)
Jim Simons 2,214,396 sh (+1578.37%)
Steven Cohen Sold Out
» More
Q3 2016

PTX Guru Trades in Q3 2016

Jim Simons 4,843,189 sh (+118.71%)
Paul Tudor Jones Sold Out
» More
Q4 2016

PTX Guru Trades in Q4 2016

Jim Simons 692,950 sh (+43.08%)
» More
» Details

Insider Trades

Latest Guru Trades with PTX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic    NAICS: 325412    SIC: 2834
Compare:NYSE:VRX » details
Traded in other countries:GTAQ.Germany,
Pernix Therapeutics Holdings Inc is a specialty pharmaceutical company focused on the sales, marketing and development of branded and generic pharmaceutical products for sleep, bacterial infections and cough and cold conditions.

Pernix Therapeutics Holdings Inc were incorporated in Maryland in November 1996. The Company is a specialty pharmaceutical company that sells, markets, manufactures and develops a number of branded and generic pharmaceutical products primarily indicated for sleep, bacterial infections and cough and cold conditions. The Company branded products includes CEDAX, an antibiotic for middle ear infections, and a family of prescription treatments for cough and cold. The Company also market SILENOR (doxepin), which is approved for the treatment of insomnia characterized by difficulty with sleep maintenance and is not a controlled substance. The Company also currently promotes Omeclamox-Pak through a License and Supply Agreement with GastroEntero-Logic, LLC; as entered into a promotion agreement with Cumberland Pharmaceuticals pursuant to which Cumberland began promoting Omeclamox-Pak to gastroenterologists. The Company also entered into an Exclusive License Agreement with Osmotica Pharmaceutical Corp. to promote its desvenlafaxine product, Khedezla Extended-Release Tablets, 50 and 100 mg. It sells its generic products in the areas of cough and cold, pain, vitamins, dermatology, antibiotics and gastroenterology through its wholly-owned subsidiaries. The Companys branded product portfolio includes; SILENOR; KHEDEZLA; CEDAX; ZUTRIPRO; REZIRA; VITUZ; and OMECLAMOX-PAK. The products of the Company face competition from a variety of similar therapeutic branded and generic products. The Companys product candidates and the activities associated with their development and commercialization, including their testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, are subject to comprehensive regulation by the FDA, the DEA and other regulatory agencies in the United States and by comparable European authorities.

Top Ranked Articles about Pernix Therapeutics Holdings Inc

Pernix: An Investor's Rationale to Staying Long The stock has fallen a bit, but there's a good reason investors are staying long
I am letting you know from the beginning, I am long Pernix Therapeutics Holdings Inc. (NASDAQ:PTX). While I may have gotten to the point where I play hide-and-seek with the daily share price fluctuations, I am far from throwing in the towel on this company. I am not stubborn to the point of becoming poor, nor do I enjoy frequent episodes of pain. Rather, I tend to have the ability to cut through the minutiae and get to the nitty gritty of the issue at hand. As such, despite Pernix's current issues, I still see significant upside value. Read more...
Major Second Quarter Purchases for Cohen Include Tesaro, Pernix Purchases 5% of company or greater available, portfolio update yet to be released
The official second quarter portfolio update for Steven Cohen (Trades, Portfolio), owner of Point72 Asset Management, has not been released as of July 20. Buys made that were greater than 5% of the company are available, however. The GuruFocus real time updates indicate Cohen purchased shares in Cynosure Inc. (CYNO), Pernix Therapeutics (NASDAQ:PTX), Tesaro Inc. (NASDAQ:TSRO) and Tetra Technologies (TTI) over the course of the second quarter. These purchases were made April 25, April 28, May 9, and June 27, respectively.  Read more...
Steven Cohen Adds to Stake in Pernix Therapeutics Company has drastically increased gross profits and net revenues over the previous 6 years
Steven Cohen (Trades, Portfolio) raised his stake in Pernix Therapeutics Holdings Inc. (NASDAQ:PTX) by nearly 49% with the purchase of 1,224,544 shares on April 28. Read more...

Ratios

vs
industry
vs
history
PS Ratio 0.16
PTX's PS Ratio is ranked higher than
99% of the 727 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.85 vs. PTX: 0.16 )
Ranked among companies with meaningful PS Ratio only.
PTX' s PS Ratio Range Over the Past 10 Years
Min: 0.07  Med: 1.52 Max: 8.94
Current: 0.16
0.07
8.94
EV-to-EBIT -2.88
PTX's EV-to-EBIT is ranked lower than
99.99% of the 545 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 20.11 vs. PTX: -2.88 )
Ranked among companies with meaningful EV-to-EBIT only.
PTX' s EV-to-EBIT Range Over the Past 10 Years
Min: -157.2  Med: -2.8 Max: 280.5
Current: -2.88
-157.2
280.5
EV-to-EBITDA 10.39
PTX's EV-to-EBITDA is ranked higher than
75% of the 573 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 16.30 vs. PTX: 10.39 )
Ranked among companies with meaningful EV-to-EBITDA only.
PTX' s EV-to-EBITDA Range Over the Past 10 Years
Min: -80.6  Med: 8.7 Max: 280.5
Current: 10.39
-80.6
280.5
Current Ratio 1.08
PTX's Current Ratio is ranked lower than
86% of the 614 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.31 vs. PTX: 1.08 )
Ranked among companies with meaningful Current Ratio only.
PTX' s Current Ratio Range Over the Past 10 Years
Min: 0.84  Med: 1.67 Max: 64.5
Current: 1.08
0.84
64.5
Quick Ratio 0.99
PTX's Quick Ratio is ranked lower than
77% of the 613 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.73 vs. PTX: 0.99 )
Ranked among companies with meaningful Quick Ratio only.
PTX' s Quick Ratio Range Over the Past 10 Years
Min: 0.62  Med: 1.46 Max: 64.5
Current: 0.99
0.62
64.5
Days Inventory 75.58
PTX's Days Inventory is ranked higher than
71% of the 626 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 115.23 vs. PTX: 75.58 )
Ranked among companies with meaningful Days Inventory only.
PTX' s Days Inventory Range Over the Past 10 Years
Min: 36.32  Med: 92.42 Max: 220.74
Current: 75.58
36.32
220.74
Days Sales Outstanding 104.05
PTX's Days Sales Outstanding is ranked lower than
70% of the 571 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 77.23 vs. PTX: 104.05 )
Ranked among companies with meaningful Days Sales Outstanding only.
PTX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 22.95  Med: 122.96 Max: 208.1
Current: 104.05
22.95
208.1

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -21.60
PTX's 3-Year Average Share Buyback Ratio is ranked lower than
83% of the 441 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: -4.00 vs. PTX: -21.60 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
PTX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -109.5  Med: -0.9 Max: 1.7
Current: -21.6
-109.5
1.7

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 0.11
PTX's Price-to-Median-PS-Value is ranked higher than
98% of the 664 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.20 vs. PTX: 0.11 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
PTX' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.07  Med: 1.42 Max: 5.26
Current: 0.11
0.07
5.26
Earnings Yield (Greenblatt) % -34.72
PTX's Earnings Yield (Greenblatt) % is ranked lower than
91% of the 788 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.86 vs. PTX: -34.72 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
PTX' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -34.72  Med: 6.5 Max: 16.7
Current: -34.72
-34.72
16.7

More Statistics

Revenue (TTM) (Mil) $157.1
EPS (TTM) $ -26.54
Beta2.23
Short Percentage of Float27.12%
52-Week Range $1.83 - 14.50
Shares Outstanding (Mil)9.50

Analyst Estimate

Dec16 Dec17 Dec18
Revenue (Mil $) 149 165 135
EPS ($) -2.90 0.10 -0.54
EPS without NRI ($) -2.90 0.10 -0.54
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for PTX

Headlines

Articles On GuruFocus.com
Pernix: An Investor's Rationale to Staying Long Mar 23 2017 
Major Second Quarter Purchases for Cohen include Tesaro, Pernix Jul 20 2016 
Steven Cohen Adds to Stake in Pernix Therapeutics Jun 07 2016 
Pernix Therapeutics Holdings Inc. Reports Operating Results (10-Q) Nov 12 2010 
Pernix Therapeutics Holdings Inc. Reports Operating Results (10-Q) Aug 16 2010 
Pernix Therapeutics Holdings Inc. Reports Operating Results (10-Q) May 14 2010 

More From Other Websites
Pernix: An Investor's Rationale to Staying Long Mar 23 2017
Webcast-Q4 Earnings Call for Pernix Therapeutics Holdings, Inc. Mar 15 2017
Pernix Therapeutics to Report Fourth Quarter and Year-End 2016 Financial Results on Tuesday, March... Mar 15 2017
Biotech's Rise Shows No Sign of Slowing Dow in 2017: Today's Reports on Pernix Therapeutics and... Feb 23 2017
Pernix Therapeutics Prevails in Zohydro® ER ANDA Litigation Feb 23 2017
Pernix Therapeutics Provides Update on Arbitration Feb 03 2017
ETFs with exposure to Pernix Therapeutics Holdings, Inc. : January 20, 2017 Jan 20 2017
Pernix Therapeutics Appoints Ken Piña as General Counsel and Chief Compliance Officer Jan 06 2017
ETFs with exposure to Pernix Therapeutics Holdings, Inc. : January 6, 2017 Jan 06 2017
Pernix Therapeutics Holdings, Inc. :PTX-US: Earnings Analysis: Q3, 2016 By the Numbers : January 5,... Jan 05 2017
Blog Coverage Teva Reports Positive Outcome for the European Label for COPAXONE®; Replaces Generics... Dec 07 2016
PERNIX THERAPEUTICS HOLDINGS, INC. Files SEC form 8-K, Change in Directors or Principal Officers Nov 29 2016
PERNIX THERAPEUTICS HOLDINGS, INC. Files SEC form 8-K, Change in Directors or Principal Officers,... Nov 22 2016
PERNIX THERAPEUTICS HOLDINGS, INC. Financials Nov 18 2016
PERNIX THERAPEUTICS HOLDINGS, INC. Files SEC form 10-Q, Quarterly Report Nov 10 2016
PERNIX THERAPEUTICS HOLDINGS, INC. Files SEC form 8-K, Change in Directors or Principal Officers,... Nov 07 2016
Drug Makers Stocks Under Scanner -- Pernix Therapeutics, Novo Nordisk, Synergy Pharma, and Apricus... Nov 01 2016
Edited Transcript of PTX earnings conference call or presentation 11-Aug-16 8:30pm GMT Oct 24 2016
ETF’s with exposure to Pernix Therapeutics Holdings, Inc. : October 14, 2016 Oct 14 2016
PERNIX THERAPEUTICS HOLDINGS, INC. Files SEC form 8-K, Material Modification to Rights of Security... Oct 13 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)